Neogenomics Inc Liquidation Value

NEO Services-Testing Laboratories

Cash & Equivalents

$146.14M
As of 2026-03-31
Current Price: N/A

Key Metrics

Cash Liquidation Value

Cash minus Total Obligations
Cash: $146.14M
Total Obligations: -$146.05M
$92,000
Per share: $0.00
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Liquid Liquidation Value

Cash + AR minus Total Obligations
Cash: $146.14M
AR: $167.42M
Total Obligations: -$146.05M
$167.52M
Per share: $1.29
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Operating Liquidation Value

Cash + AR + Inventory minus Total Obligations
Cash: $146.14M
AR: $167.42M
Inventory: $29.84M
Total Obligations: -$146.05M
$197.35M
Per share: $1.52
Period: 2026-03-31
incomplete 2 components missing — treated as $0 in formula. Why?
  • Long-Term Debt: not reported in this period (annual-only)
  • Operating Lease Liability: not reported in this period (annual-only)

Build your own liquidation scenario

Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.

Open Calculator →

Liquidation Ladder

MetricTotalPer Share
Cash Liquidation Value$92,000$0.00
Liquid Liquidation Value$167.52M$1.29
Operating Liquidation Value$197.35M$1.52

Key Components (as of 2026-03-31)

Data as of 2026-03-31 from 10-Q filed 2026-04-28. View on SEC EDGAR →

Cash & Equivalents$146.14M
Accounts Receivable$167.42M
Inventory$29.84M
Current Liabilities$84.59M
Long-term Debt (?)N/A
Op. Lease Liability (?)$61.46M
Finance Lease (?)N/A
Shares Outstanding129.7M

Explore all 123 XBRL tags and build your own scenario → Open Calculator

Historical

PeriodCashARInventoryAPCurr LiabLT DebtOp LeaseFin Lease
2026-03-31$146.14M$167.42M$29.84M$25.90M$84.59MN/A$61.46MN/A
2025-12-31$159.62M$159.24M$28.57M$23.09M$88.30M$341.86M$62.82MN/A
2025-09-30$164.12M$155.30M$28.46M$22.61M$97.87MN/A$64.33MN/A
2025-06-30$154.72M$153.12M$34.17M$27.49M$100.12MN/A$66.62MN/A
2025-03-31$346.19M$151.21M$29.77M$16.21M$279.69MN/A$59.86MN/A
2024-12-31$367.01M$150.54M$26.75M$21.61M$301.24M$340.33M$60.84MN/A
2024-09-30$361.99M$151.43M$24.46M$16.51M$296.41MN/A$62.17MN/A
2024-06-30$355.08M$146.58M$23.21M$17.19M$289.96MN/A$63.29MN/A

Comments

SEC Filings

PeriodFormFiledLink
2026-03-31 10-Q 2026-04-28 View
2025-12-31 10-K 2026-02-17 View
2025-09-30 10-Q 2025-10-28 View
2025-06-30 10-Q 2025-07-29 View
2025-03-31 10-Q 2025-04-29 View
2024-12-31 10-K 2025-02-18 View
2024-09-30 10-Q 2024-11-05 View
2024-06-30 10-Q 2024-07-30 View

AI Insights

AI Insight·Generated 2026-05-05

NeoGenomics (NEO) presents a deeply negative liquidation posture as of March 31, 2026. Under a stop-and-liquidate scenario, recoverable asset value is overwhelmed by face-value liabilities, driven primarily by a $524.0M goodwill balance and $278.9M of net intangible assets that carry zero recovery under the liquidation lens. These two line items alone represent approximately $803M of balance-sheet value that evaporates on wind-up, against total reported assets of $1,346.5M. Applied recovery haircuts across the tangible asset base produce approximately: cash $146.1M (100%), net AR $167.4M haircut to ~$152-159M (90-95%), inventory $29.8M haircut to ~$17.9M (60%), and PP&E net $83.7M haircut to ~$42-59M (50-70%). Total haircutted tangible asset recovery approximates $360-380M before consideration of operating lease ROU assets ($76.7M, minimal liquidation value) and other current/noncurrent assets. Against this, total liabilities stand at $517.8M at face, including $342.2M of the 2028 Convertible Notes (0.25% coupon, due 2028, carried at net of unamortized discount), $66.3M of ASC 842 operating lease obligations ($4.8M current + $61.5M noncurrent), $40.6M accrued compensation, $25.9M accounts payable, $17.5M deferred tax liabilities, and an $11.2M contingent OIG reserve held in other long-term liabilities. After settling all liabilities at face value from haircutted tangible assets, equity recovery is negative by a wide margin, consistent with MFFAIS CLV of $92K and LLV of $167.5M — the latter capturing only the most liquid current assets. The company continues to generate operating losses ($18.2M operating loss for Q1 2026), negative operating cash flow ($8.1M used), and carries a full U.S. valuation allowance against deferred tax assets. The 2025 Convertible Notes were retired in Q2 2025, reducing interest expense materially but also removing approximately $207M in cash that previously served as a liquidity buffer, explaining the decline in cash from $367M (Q1 2025 beginning balance) to $159.6M (December 31, 2025) and further to $146.1M at period end. The prior filing (10-K for FY2025) disclosed a $27.8M goodwill and intangible impairment charge in fiscal 2025, indicating the goodwill balance has already been tested and partially written down; however, $524M remains on the books and represents the dominant driver of the liquidation deficit. The OIG regulatory matter ($11.2M accrued, actual liability range not estimable) and the Goldenberg shareholder class action (dismissed at district court level but on appeal as of filing) add contingent liability exposure not fully reflected in the accrued reserve.

Flags

Loading flags...

AI Insight Discussion

Loading...

Community Notes

Loading notes...

Questions

Loading questions...